Mouse monoclonal antibody Anti-Human BARD1 | MyBioSource MBS120127 product information

product summary

company name :

MyBioSource

product type :

antibody

product name :

Mouse monoclonal antibody Anti-Human BARD1

catalog :

MBS120127

quantity :

0.1 mg

price :

345 USD

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

2059C4a

reactivity :

human

application :

western blot, immunoprecipitation

more info or order :

MyBioSource product webpage

product information

catalog number :

MBS120127

products type :

Antibody

products full name :

Mouse monoclonal antibody Anti-Human BARD1

products short name :

BARD1

products name syn :

Homo sapiens BRCA1 associated RING domain 1 (BARD1), mRNA

other names :

Homo sapiens BRCA1 associated RING domain 1 (BARD1), transcript variant 1, mRNA; BRCA1-associated RING domain protein 1; BRCA1-associated RING domain protein 1; BRCA1-associated RING domain gene 1; BRCA1 associated RING domain 1

products gene name :

BARD1

other gene names :

BARD1; BARD1

uniprot entry name :

BARD1_HUMAN

clonality :

Monoclonal

isotype :

IgG1

clone :

2059C4a

host :

Mouse

reactivity :

Human

sequence length :

5523

concentration :

100 ug/ml (1.0 ml)

tested application :

Dot Blot (DB), Immunoprecipitation (IP), Western Blot (WB)

other info1 :

Preparation: This antibody was purified using protein G column chromatography from culture supernatant of hybridoma cultured in a medium containing bovine IgG-depleted (approximately 95%) fetal bovine serum.

other info2 :

Sterility: Filtered through a 0.22 um membrane.

products description :

BARD1 interacts with the N-terminal region of BRCA1. In addition to its ability to bind BRCA1 in vivo and in vitro, BARD1 shares homology with the 2 most conserved regions of BRCA1: the N-terminal RING motif and the C-terminal BRCT domain. The RING motif is a cysteine-rich sequence found in a variety of proteins that regulate cell growth, including the products of tumor suppressor genes and dominant protooncogenes. The BARD1 protein also contains 3 tandem ankyrin repeats. The BARD1/BRCA1 interaction is disrupted by tumorigenic amino acid substitutions in BRCA1, implying that the formation of a stable complex between these proteins may be an essential aspect of BRCA1 tumor suppression. BARD1 may be the target of oncogenic mutations in breast or ovarian cancer. [NCBI Entrez Gene Summary]

ncbi gi num :

543583785

ncbi acc num :

NP_000456.2

ncbi gb acc num :

NM_000465

ncbi mol weight :

14,362 Da

ncbi pathways :

BARD1 Signaling Events Pathway (137959); Integrated Breast Cancer Pathway (219801); Integrated Cancer Pathway (672450); Prostate Cancer Pathway (755440); RB In Cancer Pathway (920977)

ncbi summary :

This gene encodes a protein which interacts with the N-terminal region of BRCA1. In addition to its ability to bind BRCA1 in vivo and in vitro, it shares homology with the 2 most conserved regions of BRCA1: the N-terminal RING motif and the C-terminal BRCT domain. The RING motif is a cysteine-rich sequence found in a variety of proteins that regulate cell growth, including the products of tumor suppressor genes and dominant protooncogenes. This protein also contains 3 tandem ankyrin repeats. The BARD1/BRCA1 interaction is disrupted by tumorigenic amino acid substitutions in BRCA1, implying that the formation of a stable complex between these proteins may be an essential aspect of BRCA1 tumor suppression. This protein may be the target of oncogenic mutations in breast or ovarian cancer. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2013]

uniprot summary :

BARD1: the BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Plays a central role in the control of the cell cycle in response to DNA damage. Acts by mediating ubiquitin E3 ligase activity that is required for its tumor suppressor function. Also forms a heterodimer with CSTF1/CSTF-50 to modulate mRNA processing and RNAP II stability by inhibiting pre-mRNA 3 cleavage. Colocalizes with BRCA1 into discrete subnuclear foci during S phase. Can translocate to the cytoplasm. Localizes at sites of DNA damage at double-strand breaks (DSBs); recruitment to DNA damage sites is mediated by the BRCA1-A complex. Defects in BARD1 gene are found in primary breast, ovarian and uterine cancers. Protein type: EC 6.3.2.-; EC 6.3.2.19; Ligase; Ubiquitin ligase; Ubiquitin conjugating system. Chromosomal Location of Human Ortholog: 2q35. Cellular Component: nucleoplasm; intracellular membrane-bound organelle; BRCA1-BARD1 complex; cytoplasm; nucleolus; nucleus; ubiquitin ligase complex. Molecular Function: protein binding; protein homodimerization activity; zinc ion binding; RNA binding; protein heterodimerization activity; ubiquitin-protein ligase activity; kinase binding; ligase activity. Biological Process: negative regulation of mRNA 3 -end processing; negative regulation of protein export from nucleus; regulation of phosphorylation; positive regulation of apoptosis; tissue homeostasis; positive regulation of protein catabolic process; protein ubiquitination; DNA repair; cell cycle arrest; response to DNA damage stimulus; negative regulation of apoptosis. Disease: Breast Cancer

size1 :

0.1 mg

price1 :

345 USD

more info or order :

MyBioSource product webpage